Taiwan · Delayed Price · Currency is TWD Allied Biotech Statistics
Total Valuation
Allied Biotech has a market cap or net worth of TWD 2.62 billion. The enterprise value is 2.50 billion.
| Market Cap | 2.62B |
| Enterprise Value | 2.50B |
Important Dates
The next estimated earnings date is Monday, April 20, 2026.
| Earnings Date | Apr 20, 2026 |
| Ex-Dividend Date | Jul 17, 2025 |
Share Statistics
Allied Biotech has 96.24 million shares outstanding. The number of shares has increased by 0.10% in one year.
| Current Share Class | 96.24M |
| Shares Outstanding | 96.24M |
| Shares Change (YoY) | +0.10% |
| Shares Change (QoQ) | +0.22% |
| Owned by Insiders (%) | 9.11% |
| Owned by Institutions (%) | 12.89% |
| Float | 57.94M |
Valuation Ratios
The trailing PE ratio is 20.30.
| PE Ratio | 20.30 |
| Forward PE | n/a |
| PS Ratio | 3.08 |
| PB Ratio | 2.12 |
| P/TBV Ratio | 2.12 |
| P/FCF Ratio | 20.51 |
| P/OCF Ratio | 12.06 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.76, with an EV/FCF ratio of 19.56.
| EV / Earnings | 19.28 |
| EV / Sales | 2.94 |
| EV / EBITDA | 13.76 |
| EV / EBIT | 20.74 |
| EV / FCF | 19.56 |
Financial Position
The company has a current ratio of 1.90, with a Debt / Equity ratio of 0.59.
| Current Ratio | 1.90 |
| Quick Ratio | 1.24 |
| Debt / Equity | 0.59 |
| Debt / EBITDA | 4.04 |
| Debt / FCF | 5.73 |
| Interest Coverage | 6.95 |
Financial Efficiency
Return on equity (ROE) is 10.65% and return on invested capital (ROIC) is 8.43%.
| Return on Equity (ROE) | 10.65% |
| Return on Assets (ROA) | 3.46% |
| Return on Invested Capital (ROIC) | 8.43% |
| Return on Capital Employed (ROCE) | 9.32% |
| Weighted Average Cost of Capital (WACC) | 3.49% |
| Revenue Per Employee | 21.24M |
| Profits Per Employee | 3.24M |
| Employee Count | 40 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 1.04 |
Taxes
In the past 12 months, Allied Biotech has paid 34.67 million in taxes.
| Income Tax | 34.67M |
| Effective Tax Rate | 21.12% |
Stock Price Statistics
The stock price has increased by +50.98% in the last 52 weeks. The beta is -0.06, so Allied Biotech's price volatility has been lower than the market average.
| Beta (5Y) | -0.06 |
| 52-Week Price Change | +50.98% |
| 50-Day Moving Average | 25.73 |
| 200-Day Moving Average | 20.71 |
| Relative Strength Index (RSI) | 60.32 |
| Average Volume (20 Days) | 171,498 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Allied Biotech had revenue of TWD 849.51 million and earned 129.46 million in profits. Earnings per share was 1.34.
| Revenue | 849.51M |
| Gross Profit | 308.61M |
| Operating Income | 120.34M |
| Pretax Income | 164.12M |
| Net Income | 129.46M |
| EBITDA | 175.73M |
| EBIT | 120.34M |
| Earnings Per Share (EPS) | 1.34 |
Balance Sheet
The company has 853.91 million in cash and 731.91 million in debt, with a net cash position of 122.00 million or 1.27 per share.
| Cash & Cash Equivalents | 853.91M |
| Total Debt | 731.91M |
| Net Cash | 122.00M |
| Net Cash Per Share | 1.27 |
| Equity (Book Value) | 1.23B |
| Book Value Per Share | 12.83 |
| Working Capital | 721.44M |
Cash Flow
In the last 12 months, operating cash flow was 217.13 million and capital expenditures -89.51 million, giving a free cash flow of 127.62 million.
| Operating Cash Flow | 217.13M |
| Capital Expenditures | -89.51M |
| Depreciation & Amortization | 55.39M |
| Net Borrowing | -224.04M |
| Free Cash Flow | 127.62M |
| FCF Per Share | 1.33 |
Margins
Gross margin is 36.33%, with operating and profit margins of 14.17% and 15.24%.
| Gross Margin | 36.33% |
| Operating Margin | 14.17% |
| Pretax Margin | 19.32% |
| Profit Margin | 15.24% |
| EBITDA Margin | 20.69% |
| EBIT Margin | 14.17% |
| FCF Margin | 15.02% |
Dividends & Yields
This stock pays an annual dividend of 1.25, which amounts to a dividend yield of 4.78%.
| Dividend Per Share | 1.25 |
| Dividend Yield | 4.78% |
| Dividend Growth (YoY) | 17.65% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 74.18% |
| Buyback Yield | -0.10% |
| Shareholder Yield | 4.66% |
| Earnings Yield | 4.95% |
| FCF Yield | 4.88% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Allied Biotech has an Altman Z-Score of 2.43 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.43 |
| Piotroski F-Score | 8 |